Menu
Recruiting NCT07425730

Early Myocardial Dysfunction Helps Identify Severe Refractory Pediatric Lupus

Observational Systemic Lupus Erythematosus (SLE)

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: Systemic Lupus Erythematosus (SLE). Basic parameters: 7 years — 17 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Myocardial Dysfunction in Pediatric Lupus

Overview

To investigate biomarkers to identify pediatric SR-SLE patients by non-invasive echocardiographic techniques.

Detailed description

Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease. Although therapeutic advances have improved outcomes, a significant subset remains with severe disease activity despite optimal therapy, which is recognized as the severe refractory SLE (SR-SLE).A recent study using advanced echocardiographic techniques of global longitudinal strain (GLS) have revealed that left ventricular dysfunction is common in SLE patients and correlates with disease severity.The finding underscores the potential role of early myocardial dysfunction as a phenotypic marker of SR-SLE.To our knowledge, there are no validated biomarkers to reliably identify patients with SR-SLE at an early stage, especially in the pediatric population. Therefore, this study aimed to investigate biomarkers to identify pediatric SR-SLE patients.

Primary outcome measures

  • echocardiographic measurements [Time frame: 6 months]

Eligibility criteria

Inclusion criteria

  • fulfill the American College of Rheumatology (ACR) criteria
  • disease onset at ages before 18 years

Exclusion criteria

  • patients with a history of concomitant malignancy
  • patients with active bacterial, viral, fungal, mycobacterial infection

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Observational model
Cohort

Study locations

China · 1 center
  • Shanghai Children's Medical Center — Shanghai

Identifiers

NCT: NCT07425730 · ELYZX202102 · ELYZX202102

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗